Status:
COMPLETED
A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Urinary Incontinence
Eligibility:
FEMALE
18+ years
Phase:
PHASE4
Brief Summary
The main aim of the study is to investigate whether taking Tolterodine for overactive bladder symptoms can reduce the thickness of the bladder wall, as measured by intra-vaginal ultrasound. This will ...
Eligibility Criteria
Inclusion
- Symptoms of overactive bladder (described as urinary urgency, with or without urge incontinence, usually with frequency and nocturia for more than 6 months
- Bladder wall thickness of 5mm or more
Exclusion
- Treatment in the previous four weeks with an anticholinergic drug or any drug for the treatment of overactive bladder.
- Significant stress incontinence - Urinary tract infection or a history of intermittent urinary tract infections (more than four episodes in the last two years).
- Conditions considered significant by the investigator (e.g. cystocoele, significant bladder prolapse, bladder stone, indwelling catheter etc)
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
August 1 2006
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00137397
Start Date
November 1 2004
End Date
August 1 2006
Last Update
January 27 2021
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Blackburn, Lancashire, United Kingdom, BB2 3HH
2
Pfizer Investigational Site
Harrow, Middx, United Kingdom, HA1 3UJ
3
Pfizer Investigational Site
Oxford, Oxfordshire, United Kingdom, OX3 9DU
4
Pfizer Investigational Site
Livingston, West Lothian, United Kingdom, EH54 6PP